On March 18, 2022, the Board of Directors (the Board) of Adagio Therapeutics, Inc. (the Company) appointed Jane Pritchett Henderson, the Company's principal financial officer, to serve as the Company's Chief Business Officer. Ms. Henderson will also continue to serve as the Company's Chief Financial Officer. In connection with Ms. Henderson's appointment as Chief Business Officer, the Board approved an increase in Ms. Henderson's annual base salary to $510,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | -5.24% | -23.08% | -40.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.36% | 296M | |
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- IVVD Stock
- News Invivyd, Inc.
- Adagio Therapeutics, Inc. Appoints Jane Pritchett Henderson as Chief Business Officer